金奧博(002917.SZ)募投項目變更 8470.16萬元募集資金變更為收購款項
格隆匯2月26日丨金奧博(002917.SZ)公佈,為提高公司募集資金的使用效率,提升募集資金投資回報,充分發揮募集資金對公司業務發展帶來的積極作用,公司擬對“互聯網綜合服務運營平台建設項目”和“民用爆破器材產品智能裝備製造研發及產業化項目”進行變更,將尚未使用的募集資金(分別為4014.30萬元及4455.86萬元)及利息收入和理財收益(實際金額以資金轉出當日專户餘額為準)全部變更為用於支付收購山東聖世達化工有限責任公司(以下簡稱“山東聖世達”)99.8131%股權的部分收購款項(山東聖世達99.8131%股權交易價格為1.697億元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.